MDxHealth Licenses Biomarkers for Bladder Cancer to Predictive Biosciences
Under the agreement, MDxHealth grants Predictive Biosciences exclusive rights for the use of a number of its DNA methylation biomarkers in bladder cancer testing in the United States. MDxHealth retains exclusive worldwide rights to these markers in tissue-based bladder cancer tests. In return, MDxHealth will receive upfront and milestone payments and royalties on net sales. Predictive Biosciences is one of the few diagnostic companies with a strong focus on applications in urologic oncology, including bladder cancer.
Most read news
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.